WO1998039025A3 - A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease - Google Patents

A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease Download PDF

Info

Publication number
WO1998039025A3
WO1998039025A3 PCT/GB1998/000681 GB9800681W WO9839025A3 WO 1998039025 A3 WO1998039025 A3 WO 1998039025A3 GB 9800681 W GB9800681 W GB 9800681W WO 9839025 A3 WO9839025 A3 WO 9839025A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
wall component
purified
lipid cell
diagnosis
Prior art date
Application number
PCT/GB1998/000681
Other languages
French (fr)
Other versions
WO1998039025A2 (en
Inventor
Jan Adrainus Verschoor
Anne Lenaerts
Elzbieta Johannsen
Original Assignee
Adcock Ingram Ltd
Lewin John Harvey
Jan Adrainus Verschoor
Anne Lenaerts
Elzbieta Johannsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcock Ingram Ltd, Lewin John Harvey, Jan Adrainus Verschoor, Anne Lenaerts, Elzbieta Johannsen filed Critical Adcock Ingram Ltd
Priority to APAP/P/2000/001969A priority Critical patent/AP2000001969A0/en
Priority to APAP/P/1999/001670A priority patent/AP9901670A0/en
Priority to AU66312/98A priority patent/AU6631298A/en
Priority to EP98908232A priority patent/EP0971733A1/en
Publication of WO1998039025A2 publication Critical patent/WO1998039025A2/en
Publication of WO1998039025A3 publication Critical patent/WO1998039025A3/en
Priority to US09/388,725 priority patent/US6433013B1/en
Priority to US09/696,605 priority patent/US7122577B1/en
Priority to US09/847,514 priority patent/US20020052412A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Abstract

A composition comprising a purified lipid cell-wall component or analog or derivative thereof and a suitable pharmaceutical carrier, medium, excipient or adjuvant is described. The composition is useful in prophylactic and therapeutic methods of treating a microbial infection in a subject, typically a mycobacterial infection such as tuberculosis, and immune disorders, inflammatory conditions and allergies in a subject, typically autoimmune diseases. It is also useful in diagnostic methods. The purified lipid cell-wall component is typically a purified mycolic acid or a mixture of purified mycolic acids from a bacterium which produces mycolic acids. The bacterium is from Mycobacterium, Corynebacterium, Nocardia or Rhodococcus.
PCT/GB1998/000681 1997-03-03 1998-03-03 A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease WO1998039025A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
APAP/P/2000/001969A AP2000001969A0 (en) 1997-03-03 1998-03-03 A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease.
APAP/P/1999/001670A AP9901670A0 (en) 1997-03-03 1998-03-03 A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease.
AU66312/98A AU6631298A (en) 1997-03-03 1998-03-03 A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
EP98908232A EP0971733A1 (en) 1997-03-03 1998-03-03 A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
US09/388,725 US6433013B1 (en) 1997-03-03 1999-09-02 Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
US09/696,605 US7122577B1 (en) 1997-03-03 2000-10-25 Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the treatment and diagnosis of disease
US09/847,514 US20020052412A1 (en) 1997-03-03 2001-05-02 Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ZA97/1817 1997-03-03
ZA971817 1997-03-03
ZA97/10300 1997-11-14
ZA9710300 1997-11-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/388,725 Continuation-In-Part US6433013B1 (en) 1997-03-03 1999-09-02 Composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease

Publications (2)

Publication Number Publication Date
WO1998039025A2 WO1998039025A2 (en) 1998-09-11
WO1998039025A3 true WO1998039025A3 (en) 1998-11-05

Family

ID=27143737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/000681 WO1998039025A2 (en) 1997-03-03 1998-03-03 A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease

Country Status (7)

Country Link
US (5) US6433013B1 (en)
EP (2) EP1098199B1 (en)
AP (2) AP9901670A0 (en)
AT (1) ATE402413T1 (en)
AU (1) AU6631298A (en)
DE (1) DE69839782D1 (en)
WO (1) WO1998039025A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
EP1071452A1 (en) * 1998-04-13 2001-01-31 Brigham Women's Hospital, Inc. Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
JP2000210050A (en) * 1998-11-20 2000-08-02 Asama Kasei Kk Decomposition product having immunoregulation activity, its production and food using the same
GB0106985D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
GB0106987D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeuitic agent
GB0106986D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US7066194B2 (en) * 2002-07-19 2006-06-27 Applied Materials, Inc. Valve design and configuration for fast delivery system
US6772072B2 (en) 2002-07-22 2004-08-03 Applied Materials, Inc. Method and apparatus for monitoring solid precursor delivery
PT1534330E (en) * 2002-09-06 2014-06-23 Ucl Business Plc Whole bacterial cells as immune modulator
US20050067103A1 (en) * 2003-09-26 2005-03-31 Applied Materials, Inc. Interferometer endpoint monitoring device
US20050207116A1 (en) * 2004-03-22 2005-09-22 Yatskov Alexander I Systems and methods for inter-cooling computer cabinets
WO2006007510A1 (en) * 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
WO2007041322A2 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoretic delivery of active agents conjugated to nanoparticles
JP2009522011A (en) 2005-12-30 2009-06-11 Ｔｔｉ・エルビュー株式会社 Iontophoresis system, apparatus and method for delivering an active substance to a biological interface
ES2307402B1 (en) * 2006-10-30 2009-09-30 Archivel Farma, S.L. PROFILACTIC VACCINE AGAINST TUBERCULOSIS.
US20080099436A1 (en) * 2006-10-30 2008-05-01 Michael Grimbergen Endpoint detection for photomask etching
US8158526B2 (en) 2006-10-30 2012-04-17 Applied Materials, Inc. Endpoint detection for photomask etching
EP1921200A3 (en) * 2006-11-08 2010-07-21 LG Electronics Inc. Exhaust structure for clothes dryer in apartment building
JPWO2008087803A1 (en) * 2007-01-16 2010-05-06 国立大学法人北海道大学 Liposome preparation for iontophoresis encapsulating antioxidant components
EP2047860A1 (en) * 2007-10-12 2009-04-15 Centre National De La Recherche Scientifique (Cnrs) Phamaceutical compositons comprosing actinomycete glycerol acyl derivatives antigens, their process of extractin, and their use against tuberculosis.
AU2009207923A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker YKL-40
EP3933402A1 (en) 2010-02-23 2022-01-05 University of Washington Method of making unsupported artificial mycolic acid membranes
RU2468816C1 (en) * 2011-06-23 2012-12-10 Елена Александровна Шмелева Probiotic bacterial preparation of corpuscular antigens of lipopeptidopolysaccharide corynebacteria for prevention and treatment of tuberculosis, method for preparing it
US8961804B2 (en) 2011-10-25 2015-02-24 Applied Materials, Inc. Etch rate detection for photomask etching
US8808559B2 (en) 2011-11-22 2014-08-19 Applied Materials, Inc. Etch rate detection for reflective multi-material layers etching
US8900469B2 (en) 2011-12-19 2014-12-02 Applied Materials, Inc. Etch rate detection for anti-reflective coating layer and absorber layer etching
US9805939B2 (en) 2012-10-12 2017-10-31 Applied Materials, Inc. Dual endpoint detection for advanced phase shift and binary photomasks
WO2014077723A1 (en) * 2012-11-19 2014-05-22 Shmeleva Elena Alexandrovna Method for obtaining a probiotic preparation of particulate antigens of corynebacteria, probiotic bacterial preparation for preventing and treating tuberculosis, and symbiotic strain
US8778574B2 (en) 2012-11-30 2014-07-15 Applied Materials, Inc. Method for etching EUV material layers utilized to form a photomask
EP2997371B1 (en) 2013-05-16 2018-11-07 University of Pretoria A method of diagnosing tuberculosis
AU2014312135B2 (en) * 2013-08-30 2017-09-07 Longhorn Vaccines And Diagnostics, Llc Enhancing immunity to tuberculosis
US10414819B2 (en) 2013-08-30 2019-09-17 Longhorn Vaccines And Diagnostics, Llc Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance
US10370437B2 (en) 2013-08-30 2019-08-06 Longhorn Vaccines And Diagnostics, Llc Antibodies that modulate immunity to drug resistant and latent MTB infections
GB201414369D0 (en) 2014-08-13 2014-09-24 Univ Bangor Kit and method
US10337032B2 (en) 2016-02-01 2019-07-02 The University Of Manchester Compositions and methods for recombinant biosynthesis of propane
IT202000003895A1 (en) 2020-02-25 2021-08-25 Nuovo Pignone Tecnologie Srl Method for providing protective interference to axial entry blades in a rotary machine and rotary machine.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000163A1 (en) * 1993-06-21 1995-01-05 Brigham And Women's Hospital Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods
WO1995028642A1 (en) * 1994-04-14 1995-10-26 Brown, Keith, Edwin, Frank A method for detecting the presence of a mycobacterium species and a kit and antibodies for use therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006514A (en) 1986-03-20 1991-04-09 Sawai Pharmaceutical Co., Ltd. α,α-trehalose trimycolates and pharmaceutical compositions
US5573915A (en) * 1995-06-01 1996-11-12 United States Of America Determining the ability of a compound to inhibit the cyclopropanation of mycolic acids in pathogenic mycobacteria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000163A1 (en) * 1993-06-21 1995-01-05 Brigham And Women's Hospital Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods
WO1995028642A1 (en) * 1994-04-14 1995-10-26 Brown, Keith, Edwin, Frank A method for detecting the presence of a mycobacterium species and a kit and antibodies for use therein

Also Published As

Publication number Publication date
US6433013B1 (en) 2002-08-13
EP1098199A1 (en) 2001-05-09
AP9901670A0 (en) 1999-12-31
US20020052412A1 (en) 2002-05-02
EP1098199B1 (en) 2008-07-23
US20020082296A1 (en) 2002-06-27
DE69839782D1 (en) 2008-09-04
AP2000001969A0 (en) 2000-12-31
EP0971733A1 (en) 2000-01-19
US7122577B1 (en) 2006-10-17
ATE402413T1 (en) 2008-08-15
WO1998039025A2 (en) 1998-09-11
AU6631298A (en) 1998-09-22
US20020082297A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
WO1998039025A3 (en) A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
Stewart-Tull The immunological activities of bacterial peptidoglycans
GB2252044B (en) Therapeutic agent comprising mycobacterium vaccae and components thereof useful in the treatment of chronic inflammatory conditions
McLaughlin et al. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate
WO2003047524A3 (en) Methods and compositions for modulating the immune system and uses thereof
GB0009056D0 (en) Composition comprising free amino acids
NL300174I1 (en) Use of venlafaxine or an aryloxypropanamine compound for the preparation of a medicament for the treatment of incontinence.
WO2004085628A8 (en) Lactic acid utilising bacteria and their therapeutic use
EP2172216A3 (en) Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2260769A1 (en) Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg
WO1998048646A3 (en) A dietary formulation comprising arachidonic acid and methods of use
AU7188796A (en) Mycobacterium vaccae for treatment of long term autoimmune conditions
DE69622855D1 (en) PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN LACTOBACILLUS PLANTARUM AND ARGININE
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
WO1999059617A3 (en) Immunoregulator
WO2005049056A3 (en) Immune modulator comprising whole cell rhodococcus, gordonia, nocardia, dietzia, tsukamurella or nocardioides bacteria
CZ63295A3 (en) 1 alpha-fluoro-25-hydroxy-16-en-23-in-cholecalciferol as such and for the use as a therapeutic active compound, its use for the preparation of a pharmaceutical preparation, process of its preparation and a pharmaceutical preparation based thereon
WO2000067764A3 (en) Improved method for treating mammals with modified mammalian blood
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
Johnson et al. Synthetic immunoregulating molecules: A potential bridge between cytostatic chemotherapy and immunotherapy of cancer
WO2000027429A3 (en) Vaccine against papillomatous digital dermatitis (pdd)
WO2000074715A1 (en) Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
CA2350913A1 (en) Substances wk-5344a and wk-5344b and process for producing the same
Faria et al. Spinal brucellosis: a personal experience of nine patients and a review of the literature

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09388725

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998908232

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 66312/98

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998908232

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538283

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998908232

Country of ref document: EP